Secondary Central Nervous System Lymphoma

Secondary Central Nervous System Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

16 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 9
Recruiting: 7
Ph III recruiting: 0
Growth YoY: —
Industry share: 22%
Top sponsor: Memorial Sloan Kettering Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04438044	A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL	unknown	Phase 2	61	Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY	1	Oct 12, 2022	clinicaltrials
NCT05398224	R-MTX-zanbrutinib in Secondary CNS Lymphoma	unknown	Phase 2	45	Peking UniversityOTHER	1	May 31, 2022	clinicaltrials
NCT04457869